References
- Srivastava A, Brewer AK, Mauser-Bunschoten EP, Key NS, Kitchen S, Llinas A, et al. Treatment Guidelines Working Group on Behalf of The World Federation Of Hemophilia. Guidelines for the management of hemophilia. Haemophilia. 2013 Jan; 19(1):e1-47. DOI: 10.1111/j.1365-2516.2012.02909.x
- Carcao MD. The diagnosis and management of congenital hemophilia. Semin Thromb Hemost. 2012 Oct; 38(7):727-34. DOI: 10.1055/s-0032-1326786
- Srivastava A, Santagostino E, Dougall A, Kitchen S, Sutherland M, Pipe SW, et al. WFH Guidelines for the Management of Hemophilia panelists and co-authors. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia. 2020 Aug DOI: 10.1111/hae.14046 26. Suppl 6:1-158. doi: 10.1111/hae.14046. Epub 2020 Aug 3. Erratum in: Haemophilia. 2021 Jul;27(4):699. DOI: 10.1111/hae.14308
- Khair K, Mazzucconi MG, Parra R, Santagostino E, Tsakiris DA, Hermans C, et al. Pattern of bleeding in a large prospective cohort of haemophilia A patients: A three-year follow-up of the AHEAD (Advate in HaEmophilia A outcome Database) study. Haemophilia. 2018 Jan; 24(1):85-96. DOI: 10.1111/hae.13361
- Oldenburg J, Khair K, Mazzucconi MG. Real World prospective data on bleeding frequency in 1,000 patients with hemophilia A - is the goal of zero bleeds achievable? Paper presented at: 10th Annual Congress of the European Association for Haemophilia and Allied Disorders 2017(1-3), pp. February 2017. Paris: France; 2017.
- Manco-Johnson MJ, Abshire TC, Shapiro AD, Riske B, Hacker MR, Kilcoyne R, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med. 2007; 357:535-544. DOI: 10.1056/NEJMoa067659
- Manco-Johnson MJ, Lundin B, Funk S, Peterfy C, Raunig D, Werk M, et al. Effect of late prophylaxis in hemophilia on joint status: a randomized trial. J Thromb Haemost. 2017; 15:2115-2124. DOI: 10.1111/jth.13811
- Kim JY, You CW. The prevalence and risk factors of inhibitor development of FVIII in previously treated patients with hemophilia A. Blood Res. 2019 Sep; 54(3):204-209. DOI: 10.5045/br.2019.54.3.204
- Petrini P, Valentino LA, Gringeri A, Re WM, Ewenstein B. Individualizing prophylaxis in hemophilia: a review. Expert Rev Hematol. 2015 Apr; 8(2):237-46. DOI: 10.1586/17474086.2015.1002465
- Giangrande PLF, Hermans C, O’Mahony B, de Kleijn P, Bedford M, Batorova A, et al. European principles of inhibitor management in patients with haemophilia. Orphanet J Rare Dis. 2018;13:66. DOI: 10.1186/s13023-018-0800-z
- Matino D, Makris M, Dwan K, D’Amico R, Iorio A. Recombinant factor VIIa concentrate versus plasma-derived concentrates for treating acute bleeding episodes in people with haemophilia and inhibitors. Cochrane Database Syst Rev. 2015 Dec 16; 2015(12):CD004449 DOI: 10.1002/14651858.CD004449.pub4
- Gringeri A, Mantovani LG, Scalone L, Mannucci PM; COCIS Study Group. Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group. Blood 2003; 102(07):2358-63. DOI: 10.1182/blood-2003-03-0941
- Scalone L, Mantovani LG, Mannucci PM, Gringeri A; COCIS Study Investigators. Quality of life is associated to the orthopaedic status in haemophilic patients with inhibitors. Haemophilia 2006; 12(02):154-62. DOI: 10.1111/j.1365-2516.2006.01204.x
- Morfini M, Haya S, Tagariello G, Pollmann H, Quintana M, Siegmund B, et al. European study on orthopaedic status of haemophilia patients with inhibitors. Haemophilia 2007;13:606-12. DOI: 10.1111/j.1365-2516.2007.01518.x
- Manco-Johnson MJ, Lundin B, Funk S, Peterfy C, Raunig D, Werk M, et al. Effect of late prophylaxis in hemophilia on joint status: a randomized trial. J Thromb Haemost. 2017; 15:2115-24. DOI: 10.1111/jth.13811
- Petrini P, Valentino LA, Gringeri A, Re WM, Ewenstein B. Individualizing prophylaxis in hemophilia: a review. Expert Rev Hematol. 2015; 8:237-46. DOI: 10.1586/17474086.2015.1002465
- Valentino LA, Kawji M, Grygotis M. Venous access in the management of hemophilia. Blood Rev. 2011;25:11-15. DOI: 10.1016/j.blre.2010.10.001
- Kitazawa T, Igawa T, Sampei Z, Muto A, Kojima T, Soeda T, et al. A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model. Nat Med. 2012;18(10):1570-4. DOI: 10.1038/nm.2942
- HEMLIBRA product characteristics: https://www.ema.europa.eu/en/documents/product-information/hemlibra-epar-product-information_ro.pdf
- Mahlangu J, Oldenburg J, Paz-Priel I, Negrier C, Niggli M, Mancuso ME, et al. Emicizumab prophylaxis in patients who have hemophilia A without inhibitors. N Engl J Med. 2018; 379(9):811-22. DOI: 10.1056/NEJMoa1803550
- Oldenburg J, Mahlangu JN, Kim B, Schmitt C, Callaghan MU, Young G, et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med. 2017; 377(9):809-18. DOI: 10.1056/NEJMoa1703068
- Callaghan MU, Negrier C, Paz-Priel I, Chang T, Chebon S, Lehle M, et al; Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies. Blood. 2021 Apr 22; 137(16):2231-42. DOI: 10.1182/blood.2020009217
- Gelbenegger G, Schoergenhofer C, Knoebl P, Jilma B. Bridging the Missing Link with Emicizumab: A Bispecific Antibody for Treatment of Hemophilia A. Thromb Haemost. 2020 Oct; 120(10):1357-70. DOI: 10.1055/s-0040-1714279
- Paz-Priel I, Chang T, Asikanius E, Chebon S, Emrich T, Fernandez E. Immunogenicity of Emicizumab in People with Hemophilia A (PwHA): Results from the HAVEN 1-4 Studies. Blood. 2018;1329S1):633. DOI: 10.1182/blood-2018-99-118492
- Food and Drug Administration. HEMLIBRA® (emicizumab-kxwh) injection for subcutaneous use, prescribing information. Initial U.S. approval: 2017. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761083s000lbl.pdf. Accessed January 9, 2019.
- Sampei Z, Igawa T, Soeda T, Okuyama-Nishida Y, Moriyama C, Wakabayashi T, et al. Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity. PLoS One. 2013;8(2):e57479. DOI: 10.1371/journal.pone.0057479
- Lenting PJ, Denis CV, Christophe OD. Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII? Blood. 2017; 130(23):2463-68. DOI: 10.1182/blood-2017-08-801662
- Castaman G, Santoro C, Coppola A, Mancuso ME, Santoro RC, Bernardini S, et al. Emergency management in patients with haemophilia A and inhibitors on prophylaxis with emicizumab: AICE practical guidance in collaboration with SIBioC, SIMEU, SIMEUP, SIPMeL and SISET. Blood Transfus. 2020 Mar; 18(2):143-51. DOI: 10.2450/2019.0186-19
- Jonsson F, Mercier F, Prins NH, Schmitt C, Retout S. Exposure-Response Modeling of Emicizumab for the Prophylaxis of Bleeding in Hemophilia A Patients. 27th Meeting of the Population Approach Group in Europe (PAGE): Montreux, Switzerland; 2018.
- Müller J, Pekrul I, Pötzsch B, Berning B, Oldenburg J, Spannagl M. Laboratory Monitoring in Emicizumab-Treated Persons with Hemophilia A. Thromb Haemost. 2019 Sep; 119(9):1384-93. DOI: 10.1055/s-0039-1692427
- Adamkewicz JI, Chen DC, Paz-Priel I. Effects and Interferences of Emicizumab, a Humanised Bispecific Antibody Mimicking Activated Factor VIII Cofactor Function, on Coagulation Assays. Thromb Haemost. 2019 Jul; 119(7):1084-93. DOI: 10.1055/s-0039-1688687
- Nardi MA. Emicizumab and the clinical laboratory. American Society for Clinical Laboratory Science. 2020:ascls.119.002204. DOI: 10.29074/ascls.119.002204
- Jonsson F, Schmitt C, Petry C, Mercier F, Frey N, Retout S. Exposure-Bleeding Count Modeling of Emicizumab for the Prophylaxis of Bleeding in Persons with Hemophilia A with/Without Inhibitors Against Factor VIII. Clin Pharmacokinet. 2021 Jul;60(7):931-41. DOI: 10.1007/s40262-021-01006-0
- Giangrande PL, Wilde JT, Madan B, Ludlam CA, Tuddenham EG, Goddard NJ, et al. Consensus protocol for the use of recombinant activated factor VII [eptacog alfa (activated); NovoSeven] in elective orthopaedic surgery in haemophilic patients with inhibitors. Haemophilia. 2009 Mar;15(2):501-8. DOI: 10.1111/j.1365-2516.2008.01952.x